Limited coverage criteria – risperidone

Last updated on July 22, 2026

 

Return to Special Authority drug list 

Generic name

risperidone

Strength & form

75 mg, 100 mg powder for extended-release suspension for intramuscular injection

Special Authority criteria

Approval period

Management of the manifestations of schizophrenia or related psychotic disorders (not dementia-related) in:

  • Patients who have tried oral aripiprazole, risperidone or paliperidone, and
    • At least one other antipsychotic agent, and
    • Who continue to be inadequately controlled at maximally-tolerated doses

OR

  • Patients who are currently receiving a conventional depot antipsychotic, and
    • Are experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia

OR

  • Patients with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations

Indefinite

Practitioner exemptions

  • None

Special notes

  • Criteria applicable to all plans including Plan G
  • Coverage is not available for this formulation under Plan P

Special Authority request form(s)